Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in an Autism Spectrum Disorder Population

NCT04895215 is registered in ClinicalTrials.gov with Vertero Therapeutics as lead sponsor.

NCT NCT04895215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of AB-2004 in an Autism Spectrum Disorder Population
Lead sponsor
Vertero Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 2, 2021
Completion date
December 15, 2023
Enrollment
156 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder (asd)